Literature DB >> 30996771

Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.

Valentina Sepe1, Silvia Marchianò2, Claudia Finamore1, Giuliana Baronissi1, Francesco Saverio Di Leva1, Adriana Carino2, Michele Biagioli2, Chiara Fiorucci2, Chiara Cassiano3, Maria Chiara Monti3, Federica Del Gaudio3, Ettore Novellino1, Vittorio Limongelli1,4, Stefano Fiorucci2, Angela Zampella1.   

Abstract

Acetaminophen misuse is a leading cause of acute liver failure and liver transplantation for which therapy is poorly effective. FXR ligands have shown effective in reducing liver injury in several experimental and clinical settings. In this Letter, we have elaborated on the structure of GW4064, the first nonsteroidal agonist for FXR, to identify novel isoxazoles endowed with FXR agonistic activity and improved ADME properties. The pharmacological characterization and molecular docking studies for the structure-activity rationalization allowed the identification of several FXR agonists with nanomolar potency in transactivation and SRC-1 recruitment assays. This characterization resulted in the identification of a potent FXR agonist, compound 20 that was orally active, and rescued mice from acute liver failure caused by acetaminophen overdose in a FXR-dependent manner.

Entities:  

Year:  2018        PMID: 30996771      PMCID: PMC6466548          DOI: 10.1021/acsmedchemlett.8b00423

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  28 in total

1.  Identification of a chemical tool for the orphan nuclear receptor FXR.

Authors:  P R Maloney; D J Parks; C D Haffner; A M Fivush; G Chandra; K D Plunket; K L Creech; L B Moore; J G Wilson; M C Lewis; S A Jones; T M Willson
Journal:  J Med Chem       Date:  2000-08-10       Impact factor: 7.446

Review 2.  Acetaminophen hepatoxicity: what do we know, what don't we know, and what do we do next?

Authors:  Neil Kaplowitz
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

3.  Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.

Authors:  Yanqiao Zhang; Florence Ying Lee; Gabriel Barrera; Hans Lee; Charisse Vales; Frank J Gonzalez; Timothy M Willson; Peter A Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-12       Impact factor: 11.205

4.  Identification of a nuclear receptor for bile acids.

Authors:  M Makishima; A Y Okamoto; J J Repa; H Tu; R M Learned; A Luk; M V Hull; K D Lustig; D J Mangelsdorf; B Shan
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

5.  Bile acids: natural ligands for an orphan nuclear receptor.

Authors:  D J Parks; S G Blanchard; R K Bledsoe; G Chandra; T G Consler; S A Kliewer; J B Stimmel; T M Willson; A M Zavacki; D D Moore; J M Lehmann
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

6.  The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.

Authors:  Stefano Fiorucci; Elisabetta Antonelli; Giovanni Rizzo; Barbara Renga; Andrea Mencarelli; Luisa Riccardi; Stefano Orlandi; Roberto Pellicciari; Antonio Morelli
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Prevention of cholesterol gallstone disease by FXR agonists in a mouse model.

Authors:  Antonio Moschetta; Angie L Bookout; David J Mangelsdorf
Journal:  Nat Med       Date:  2004-11-21       Impact factor: 53.440

8.  Structural basis for bile acid binding and activation of the nuclear receptor FXR.

Authors:  Li-Zhi Mi; Srikripa Devarakonda; Joel M Harp; Qing Han; Roberto Pellicciari; Timothy M Willson; Sepideh Khorasanizadeh; Fraydoon Rastinejad
Journal:  Mol Cell       Date:  2003-04       Impact factor: 17.970

9.  Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.

Authors:  C J Sinal; M Tohkin; M Miyata; J M Ward; G Lambert; F J Gonzalez
Journal:  Cell       Date:  2000-09-15       Impact factor: 41.582

10.  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

Authors:  Roberto Pellicciari; Stefano Fiorucci; Emidio Camaioni; Carlo Clerici; Gabriele Costantino; Patrick R Maloney; Antonio Morelli; Derek J Parks; Timothy M Willson
Journal:  J Med Chem       Date:  2002-08-15       Impact factor: 7.446

View more
  4 in total

1.  Structure-Activity Relationship Studies of Trisubstituted Isoxazoles as Selective Allosteric Ligands for the Retinoic-Acid-Receptor-Related Orphan Receptor γt.

Authors:  Femke A Meijer; Annet O W M Saris; Richard G Doveston; Guido J M Oerlemans; Rens M J M de Vries; Bente A Somsen; Anke Unger; Bert Klebl; Christian Ottmann; Peter J Cossar; Luc Brunsveld
Journal:  J Med Chem       Date:  2021-05-19       Impact factor: 7.446

2.  Protein-ligand binding with the coarse-grained Martini model.

Authors:  Paulo C T Souza; Sebastian Thallmair; Paolo Conflitti; Carlos Ramírez-Palacios; Riccardo Alessandri; Stefano Raniolo; Vittorio Limongelli; Siewert J Marrink
Journal:  Nat Commun       Date:  2020-07-24       Impact factor: 14.919

3.  Synthesis of Novel Farnesoid X Receptor Agonists and Validation of Their Efficacy in Activating Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Osteoblasts.

Authors:  Ko Fujimori; Yusuke Iguchi; Yukiko Yamashita; Keigo Gohda; Naoki Teno
Journal:  Molecules       Date:  2019-11-16       Impact factor: 4.411

Review 4.  Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists.

Authors:  Ludovico Abenavoli; Anna Caterina Procopio; Sharmila Fagoonee; Rinaldo Pellicano; Marco Carbone; Francesco Luzza; Pietro Invernizzi
Journal:  Diseases       Date:  2020-06-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.